Patient and donor characteristics
| Variable . | Cohort 1 (multicentric) . | Cohort 2 (monocentric) . | ||
|---|---|---|---|---|
| Donors (n = 39) . | Recipients (n = 38) . | Donors (n = 42) . | Recipients (n = 37) . | |
| Age, median (range), y | 49.5 (14-65) | 46 (17-68) | 52.5 (15-67) | 53 (22-67) |
| Sex | ||||
| Female | 18 (46.1) | 19 (50) | 24 (57.1) | 19 (51.4) |
| Male | 20 (51.3) | 19 (50) | 18 (42.9) | 18 (48.6) |
| Unknown | 1 (2.6) | — | — | — |
| HLA-identical sibling donor, % | 100 | 100 | ||
| Graft type | ||||
| Bone marrow | 11 (28.9) | 3 (8.1) | ||
| Peripheral blood | 26 (68.5) | 34 (91.9) | ||
| Unknown | 1 (2.6) | — | ||
| Sex match | ||||
| Male to male | 10 (26.3) | 7 (18.9) | ||
| Female to female | 9 (23.7) | 11 (29.7) | ||
| Male to female | 10 (26.3) | 8 (21.7) | ||
| Female to male | 8 (21.1) | 11 (29.7) | ||
| Unknown | 1 (2.6) | — | ||
| Conditioning regimen | ||||
| Reduced intensity | 17 (44.8) | 32 (86.5) | ||
| Myeloablative | 20 (52.6) | 5 (13.5) | ||
| Unknown | 1 (2.6) | — | ||
| Total body irradiation | ||||
| Yes | 12 (31.6) | 4 (10.8) | ||
| No | 25 (65.8) | 33 (89.2) | ||
| Unknown | 1 (2.6) | — | ||
| Chimerism, median (range), % | ||||
| No GVHD | 100 (86-100) | 100 (60-100) | ||
| GVHD | 100 (81-100) | 100 (97-100) | ||
| Unknown | 4 (10.5) | — | ||
| GVHD status | ||||
| GVHD | 16 (42.1) | 19 (51.4) | ||
| No GVHD | 22 (57.9) | 18 (48.6) | ||
| GVHD grade | ||||
| Grade 1 | 8 (50) | 1 (5.3) | ||
| Grade 2 | 5 (31.1) | 16 (84.1) | ||
| Grade 3 | 1 (6.3) | 1 (5.3) | ||
| Grade 4 | 1 (6.3) | 1 (5.3) | ||
| Unknown | 1 (6.3) | — | ||
| Delay sample-graft, median (range), d | ||||
| Donors | −27 (−136 to 0) | −27 (−119 to −1) | ||
| GVHD onset | 29 (12-91) | 36 (9-94) | ||
| No GVHD | 91 (27-108) | 90 (77-95) | ||
| GVHD prophylaxis | ||||
| CSA | 7 (18.4) | 2 (5.4) | ||
| CSA+MMF | 8 (21.1) | 26 (70.3) | ||
| CSA+MTX | 22 (57.9) | 8 (21.6) | ||
| None | 0 | 1 (2.7) | ||
| Unknown | 1 (2.6) | — | ||
| Diagnosis | ||||
| Acute leukemia | 17 (44.7) | 13 (35.2) | ||
| Myeloproliferative neoplasm | 3 (7.9) | 8 (21.6) | ||
| Lymphoma | 8 (21.1) | 5 (13.5) | ||
| Myeloma | 2 (5.3) | 3 (8.1) | ||
| Myelodysplastic syndrome | 4 (10.5) | 2 (5.4) | ||
| Aplastic anemia | 1 (2.6) | 3 (8.1) | ||
| Chronic lymphoid leukemia | 1 (2.6) | 2 (5.4) | ||
| Other diagnosis | 2 (5.3) | 1 (2.7) | ||
| CMV serostatus | ||||
| Positive | 22 (56.4) | 20 (52.6) | 23 (54.8) | 29 (78.4) |
| Negative | 16 (41) | 16 (42.1) | 19 (45.2) | 8 (21.6) |
| Unknown | 1 (2.6) | 2 (5.3) | — | — |
| CMV status mismatch | ||||
| D+/R+ | 13 (34.2) | 21 (56.8) | ||
| D−/R− | 8 (21.1) | 7 (18.9) | ||
| D+/R− | 8 (21.1) | 1 (2.7) | ||
| D−/R+ | 7 (18.4) | 8 (21.6) | ||
| Variable . | Cohort 1 (multicentric) . | Cohort 2 (monocentric) . | ||
|---|---|---|---|---|
| Donors (n = 39) . | Recipients (n = 38) . | Donors (n = 42) . | Recipients (n = 37) . | |
| Age, median (range), y | 49.5 (14-65) | 46 (17-68) | 52.5 (15-67) | 53 (22-67) |
| Sex | ||||
| Female | 18 (46.1) | 19 (50) | 24 (57.1) | 19 (51.4) |
| Male | 20 (51.3) | 19 (50) | 18 (42.9) | 18 (48.6) |
| Unknown | 1 (2.6) | — | — | — |
| HLA-identical sibling donor, % | 100 | 100 | ||
| Graft type | ||||
| Bone marrow | 11 (28.9) | 3 (8.1) | ||
| Peripheral blood | 26 (68.5) | 34 (91.9) | ||
| Unknown | 1 (2.6) | — | ||
| Sex match | ||||
| Male to male | 10 (26.3) | 7 (18.9) | ||
| Female to female | 9 (23.7) | 11 (29.7) | ||
| Male to female | 10 (26.3) | 8 (21.7) | ||
| Female to male | 8 (21.1) | 11 (29.7) | ||
| Unknown | 1 (2.6) | — | ||
| Conditioning regimen | ||||
| Reduced intensity | 17 (44.8) | 32 (86.5) | ||
| Myeloablative | 20 (52.6) | 5 (13.5) | ||
| Unknown | 1 (2.6) | — | ||
| Total body irradiation | ||||
| Yes | 12 (31.6) | 4 (10.8) | ||
| No | 25 (65.8) | 33 (89.2) | ||
| Unknown | 1 (2.6) | — | ||
| Chimerism, median (range), % | ||||
| No GVHD | 100 (86-100) | 100 (60-100) | ||
| GVHD | 100 (81-100) | 100 (97-100) | ||
| Unknown | 4 (10.5) | — | ||
| GVHD status | ||||
| GVHD | 16 (42.1) | 19 (51.4) | ||
| No GVHD | 22 (57.9) | 18 (48.6) | ||
| GVHD grade | ||||
| Grade 1 | 8 (50) | 1 (5.3) | ||
| Grade 2 | 5 (31.1) | 16 (84.1) | ||
| Grade 3 | 1 (6.3) | 1 (5.3) | ||
| Grade 4 | 1 (6.3) | 1 (5.3) | ||
| Unknown | 1 (6.3) | — | ||
| Delay sample-graft, median (range), d | ||||
| Donors | −27 (−136 to 0) | −27 (−119 to −1) | ||
| GVHD onset | 29 (12-91) | 36 (9-94) | ||
| No GVHD | 91 (27-108) | 90 (77-95) | ||
| GVHD prophylaxis | ||||
| CSA | 7 (18.4) | 2 (5.4) | ||
| CSA+MMF | 8 (21.1) | 26 (70.3) | ||
| CSA+MTX | 22 (57.9) | 8 (21.6) | ||
| None | 0 | 1 (2.7) | ||
| Unknown | 1 (2.6) | — | ||
| Diagnosis | ||||
| Acute leukemia | 17 (44.7) | 13 (35.2) | ||
| Myeloproliferative neoplasm | 3 (7.9) | 8 (21.6) | ||
| Lymphoma | 8 (21.1) | 5 (13.5) | ||
| Myeloma | 2 (5.3) | 3 (8.1) | ||
| Myelodysplastic syndrome | 4 (10.5) | 2 (5.4) | ||
| Aplastic anemia | 1 (2.6) | 3 (8.1) | ||
| Chronic lymphoid leukemia | 1 (2.6) | 2 (5.4) | ||
| Other diagnosis | 2 (5.3) | 1 (2.7) | ||
| CMV serostatus | ||||
| Positive | 22 (56.4) | 20 (52.6) | 23 (54.8) | 29 (78.4) |
| Negative | 16 (41) | 16 (42.1) | 19 (45.2) | 8 (21.6) |
| Unknown | 1 (2.6) | 2 (5.3) | — | — |
| CMV status mismatch | ||||
| D+/R+ | 13 (34.2) | 21 (56.8) | ||
| D−/R− | 8 (21.1) | 7 (18.9) | ||
| D+/R− | 8 (21.1) | 1 (2.7) | ||
| D−/R+ | 7 (18.4) | 8 (21.6) | ||
Unless otherwise noted, data are n (%).
CMV, cytomegalovirus; CSA, cyclosporine A; D, donor; MMF, mycophenolate mofetil; MTX, methotrexate; R, recipient; —, none; −, negative; +, positive.